Improving treatment for chronic lymphocytic leukemia by rational use of monoclonal antibodies.
Department of Translational Oncology, National Center for Tumor Diseases, Heidelberg, Germany.
Mikołaj
M
Słabicki
Thorsten
T
Zenz
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003167:Complement Activation; D003165:Complement System Proteins / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab; D003165:Complement System Proteins; C527517:ofatumumab